Co-Director of MTCPG, University of Malaya, Adjunct Researcher, Monash University, Associate Director, Certara
Monash University
Dr Yu-Wei (Wayne) Lin is the co-director (co-group lead) of the Malaya Translational and Clinical Pharmacometrics Group (MTCPG, University of Malaya), an antimicrobial pharmacologist at Monash University, Australia, and a pharmacometrics consultant (associate director) for Certara, USA/Australia/Europe. He has over 7 years of academic research experience in antimicrobial pharmacokinetics/pharmacodynamics/ toxicodynamics (PK/PD/TD) and systems pharmacology and, >2+ years of experience in drug development in numerous areas, including oncology, immunology, rare disease and infectious disease. Over the past 7 years, his research has focused on optimising the dosage regimens of inhaled antibiotic mono- and combination therapies and the development of novel anti-bacterial therapy against Gram-negative ‘superbugs’. Moreover, as an associate director, he has knowledge and experience in model-informed drug development, FDA filling and designing clinical trials (including first-in-human studies and clinical pharmacology studies). Since 2015, Dr Lin has published 39 papers in antimicrobial research including 37 original research articles (9 as first-author; 2 as first and co-corresponding author; 1 as co-corresponding author), two invited first-author review; 12 of these were published in the most cited journal in the field of pharmacology and toxicology, namely Antimicrobial Agents and Chemotherapy (1/274; Journal of Citation Report 2017). The quality and impact of his research have been recognised with 2 best oral presentation prizes, 1 fellowship, 4 prestigious research grants (including an NIH R21), 5 travel grants and 5 research awards, most notably among them being the ASCEPT New Investigator Award.
Disclosure information not submitted.
Friday, May 13, 2022
8:00 AM – 12:00 PM ET
.png)